Home > Boards > US Listed > Biotechs >

MannKind Corp. (MNKD)

Add MNKD Price Alert      Hide Sticky   Hide Intro
Moderator: Peaser, conix, MadHatter326, KingDMC, $Pistol Pete$
Search This Board:
Last Post: 2/12/2016 8:58:58 PM - Followers: 343 - Board type: Free - Posts Today: 31


About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for patients.

AFREZZA® (pronounced uh-FREZZ-uh) is a rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes. AFREZZA was approved by the FDA in 2014. MannKind has a global licensing agreement with Sanofi for the development and commercialization of AFREZZA. Sanofi is responsible for global commercial, regulatory and development activities and. MannKind manufactures AFREZZA at its manufacturing facility in Danbury, CT.

AFREZZA utilizes our proprietary Technosphere® formulation technology , which is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded.  We believe Technosphere represents a versatile drug delivery platform that may allow pulmonary administration of certain drugs that currently require administration by injection, such as GLP-1. Pulmonary administration provides convenience for the patient and we believe a major advantage of drugs inhaled as Technosphere formulations is that they have been shown to be absorbed very rapidly into the arterial circulation, essentially mimicking intra-arterial administration. MannKind is also developing other inhalation technologies, including an innovative line of patient-focused, breath-activated, dry powder inhalers and inhalation profiling to characterize patient inhalation.

- See more at:


Board of Directors

Alfred E. Mann

Alfred E. Mann has been one of our directors since April 1999, our Chairman of the Board since December 2001 and our Executive Chairman since January 2015. He also served as our Chief Executive Officer from October 2003 until January 2015.  Mr. Mann has founded and largely funded 14 companies in his career.  Nine were acquired at an overall total of almost $8 billion, and three companies became public.  In addition to MannKind, he is currently involved with:

• Bioness, which develops and manufactures systems to address neural deficits and to restore controlled function of paralyzed limbs;
• Second Sight, which is developing a visual prosthesis to restore sight to the blind; 
• IncuMed, which is developing novel percutaneous seals for various applications; 
• PerQFlo, which is developing drug delivery systems; and
• RoundTrip, which is developing location and identification technology.

In 1993, Mr. Mann founded and served as Chairman and Chief Executive Officer of MiniMed Inc. until August 2001 when it was acquired by Medtronic, Inc.  Medtronic MiniMed develops, manufactures and distributes microinfusion systems and continuous glucose monitoring systems that have revolutionized the treatment of Type 1 diabetes.  Mr. Mann founded and funded Medical Research Group (MRG), a developer of an artificial pancreas.  MRG was also acquired by Medtronic in 2001.  Mr. Mann also founded and served as the Chairman of the Board and Chief Executive Officer of Advanced Bionics Corporation from its founding in 1993 until it was acquired by Boston Scientific Corporation in 2004.  Advanced Bionics developed neurostimulation devices for various neural deficits, including cochlear stimulators.  Previously, Mr. Mann founded and was Chairman of the Board and CEO of Pacesetter Systems, Inc., which developed, manufactured and distributed cardiac pacemakers, from 1972 until 1985 when it was acquired by Siemens, AG.  From 1985 to September 1992, Mr. Mann continued to serve as Chairman and CEO of the successor company, Siemens-Pacesetter, Inc., Pacesetter is now the Cardiac Rhythm Management unit of St. Jude Medical.  Prior to 1972, he was President of Spectrolab, an electro-optical and aerospace systems company, and Heliotek, a semiconductor and electro-optical components manufacturer.  Mr. Mann founded these companies in 1956 and 1960, respectively, sold them to Textron Inc. in 1960 and continued to lead them until 1972, when he left for Pacesetter.  They are now part of the Boeing Company.
Mr. Mann founded and endowed, and from 1985 until 2006 served as Chairman of the Board of Trustees of The Alfred Mann Foundation, a nonprofit research organization devoted to development of advanced medical products in a variety of fields.  Mr. Mann is currently Chairman of the Board of Trustees of the Alfred Mann Institutes at the University of Southern California, Purdue University, and The Technion Institute (Israel), all of these medical research foundations founded and endowed principally by Mr. Mann.  He also serves as a Trustee for the University of Southern California, as a member of the Board of Overseers of the Keck USC School of Medicine, and as the Chairman of the Southern California Biomedical Council, a nonprofit association dedicated to the fostering of the bio-medical industry in the Los Angeles Metropolitan area.  Alfred Mann also serves as a Director of the Nevada Cancer Institute.
Mr. Mann holds B.A. and M.S. degrees in physics from the University of California, Los Angeles and honorary doctorate degrees from the University of Southern California, The Johns Hopkins University, Western University and the Technion Institute (Israel).  Mr. Mann is also a member of the National Academy of Engineering.

Ronald Consiglio


Ronald J. Consiglio has been one of our directors since October 2003. Since 1999, Mr. Consiglio has been the managing director of Synergy Trading, a securities-trading partnership. From 1999 to 2001, Mr. Consiglio was Executive Vice President and Chief Financial Officer of Trading Edge, Inc., a national automated bond-trading firm. From January 1993 to 1998 Mr. Consiglio served as Chief Executive Officer of Angeles Mortgage Investment Trust, a publicly traded Real Estate Investment Trust. His prior experience includes serving as Senior Vice President and Chief Financial Officer of Cantor Fitzgerald & Co. and as a member of its board of directors. Mr. Consiglio has served as a member of the board of trustees for the Metropolitan West Funds since 2003. Mr. Consiglio is a certified public accountant and holds a bachelor’s degree in accounting from California State University at Northridge  A good forum for discussion on Mankind

MannKind Corporation, a development stage company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of diabetes and cancer. Its lead investigational product candidate, the Technosphere Insulin System, is in phase III clinical trials in the United States, Europe, and Latin America for the treatment of diabetes. This dry powder therapy consists of Technosphere particles onto which insulin molecules are loaded. These loaded particles are then aerosolized and inhaled into the deep lung using its proprietary MedTone inhaler. The company is also developing therapies for the treatment of solid tumor cancers. The lead product candidate in this program, MKC1106-PP, which is in phase I clinical trial is intended for the treatment of various solid-tumor cancers, including ovarian, colorectal, pancreatic, renal, breast, and prostate carcinomas and melanoma. MannKind was founded in 1991 and is headquartered in Valencia, CA.;;




  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
MNKD News: Harwood Feffer LLP Announces Investigation of MannKind Corporation 04:13 PM
MNKD News: IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against MannKind Corp. & Encourages Inves... 02/10/2016 03:44:00 PM
MNKD News: INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MannKind Corp. of Class Action Lawsuit and a Lead Plaintiff Dea... 02/10/2016 02:52:37 PM
MNKD News: IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against MannKind Corp. & Encourages I... 02/09/2016 09:55:00 PM
MNKD News: SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in MannKind Corp. ... 02/08/2016 08:00:00 PM
News News Alert: Harwood Feffer LLP Announces Investigation of MannKind Corporation 02/12/2016 04:13:00 PM
#17438  Sticky Note MNKD Manipulation Story: Peaser 02/01/16 09:03:36 AM
#16574  Sticky Note $MNKD ~ MannKind Corp. due diligence report $Pistol Pete$ 12/18/15 01:14:52 AM
#15987  Sticky Note SHORT INTEREST: 10/30/2015 ---120,021,454 conix 11/11/15 10:08:03 PM
#8377  Sticky Note Not Looking Good For MNKD! MadHatter326 02/13/15 02:37:35 PM
#17632   here is the key point about MNKD TREND1 02/12/16 08:58:58 PM
#17631   no TREND1 02/12/16 08:55:13 PM
#17630   Well ya , duh ! Are you not Brentpdc 02/12/16 08:54:31 PM
#17629   lawsuits TREND1 02/12/16 08:53:47 PM
#17628   What do you mean insurance ? Insurance for Brentpdc 02/12/16 08:48:02 PM
#17627   CEO says they have insurance . TREND1 02/12/16 08:46:49 PM
#17626   What about the recent lawsuit? It should drive Brentpdc 02/12/16 08:45:28 PM
#17625   BUY IT NOW , If you wait, you TREND1 02/12/16 08:44:46 PM
#17624   As anew comer this stock has huge potential Brentpdc 02/12/16 08:21:30 PM
#17623   How is this bad news? Brentpdc 02/12/16 07:02:59 PM
#17622   The deal ends this April ? Brentpdc 02/12/16 06:58:44 PM
#17621   So why is this so cheep ? Shorted exwannabe 02/12/16 06:54:07 PM
#17620   Only 2.7 million dollars traded in MNKD stock today. TREND1 02/12/16 06:50:00 PM
#17619   "Seeking Alpha is intentionally misleading investors for their Peaser 02/12/16 06:25:25 PM
#17618   A very, very long story. You can start Peaser 02/12/16 06:04:13 PM
#17617   So why is this so cheep ? Shorted Brentpdc 02/12/16 05:51:16 PM
#17616   That is the opinion of many. Peaser 02/12/16 05:48:46 PM
#17615   This will be huge ? Brentpdc 02/12/16 04:53:01 PM
#17614   New Facebook group created: Peaser 02/12/16 04:45:41 PM
#17612   ROFL. Good luck ever picking anything up below Peaser 02/12/16 03:05:58 PM
#17611 Peaser 02/12/16 02:54:09 PM
#17610   .82-.85 load up again harry crumb 02/12/16 12:37:34 PM
#17609   MNKD 10 MINUTES TREND1 02/12/16 10:21:25 AM
#17608   quote ......................................................... come April wh TREND1 02/12/16 10:15:56 AM
#17607   A SNY settlement, along with Script numbers will Peaser 02/12/16 09:42:35 AM
#17606   TV ADS by SNY are old history on TREND1 02/12/16 09:39:29 AM
#17605   Really, where is the evidence that they put Peaser 02/12/16 08:59:55 AM
#17604 Peaser 02/12/16 01:19:40 AM
#17603   SNY did test markets with TV ADS. TREND1 02/12/16 12:18:16 AM
#17602   It will be very interesting to see how Peaser 02/12/16 12:09:13 AM
#17601   You're hilarious. Hope you get your .90 to Peaser 02/11/16 11:46:50 PM
#17600   WOW That is bad news . TREND1 02/11/16 11:25:28 PM
#17599   Out of 20 major shareholders 6 no change, Peaser 02/11/16 11:03:45 PM
#17598   QUOTE ........................................................... I'm right o TREND1 02/11/16 08:31:09 PM
#17597   I'm right on both stocks!!! Science never stops! md1225 02/11/16 07:58:34 PM
#17596   It would be great to be a high kugel 02/11/16 02:35:39 PM
#17595   very clear and good post. IMHO TREND1 02/11/16 11:34:21 AM
#17594   ***** MNKD 10 MINUTES TREND1 02/11/16 10:38:42 AM
#17593   md1225 I hear the same thing from you Hypi 02/11/16 09:30:22 AM
#17592   1 Thank you for the information WHS 02/11/16 06:22:41 AM
#17591   Interesting... Green days are ahead, imo! Peaser 02/10/16 06:25:59 PM
#17590   TRADE IT TREND1 02/10/16 04:06:53 PM
#17589   Yes it amazing what happens when a miracle md1225 02/10/16 03:36:19 PM
#17588   MD1225 Your story on MNKD says that by TREND1 02/10/16 03:21:56 PM
#17587   Speaking of Afrezza safety... Peaser 02/10/16 02:36:27 PM
#17586   $MNKD 15' Chart $Pistol Pete$ 02/10/16 02:17:50 PM
#17584  Restored CEO Matt Pfeffer followed me on Twitter today! md1225 02/10/16 01:41:59 PM
#17583   MD1225 It is an easy calculation to find out TREND1 02/10/16 12:42:37 PM
#17582   QUOTE ............................................................ Sales of Afreeza could easily h TREND1 02/10/16 12:11:29 PM
#17581   ***** MNKD 10 MINUTES TREND1 02/10/16 11:33:54 AM